Skip to main content

Advertisement

SpringerLink
Log in

Potential of alfacalcidol for reducing increased risk of falls and fractures

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

There are no general accepted strategies for combined drug treatments in osteoporosis, while in other important chronic diseases combinations of different medications are used as a rule to improve therapeutic results and reduce the risk of adverse events. It is suggested that the success of combined treatments is related to the different modes of action of the respective single therapies. On the other hand it was shown that a strong antiresorptive bisphosphonate is able to blunt at least in part the effects of anabolic parathyroid hormone peptides Calcitriol, the active vitamin D-hormone and its prodrug alfacalcidol lead to pleiotropic effects on bone remodelling (antiresorptive, anabolic and enhancing mineralization) and in addition to effects on other important target tissues (e.g. gut, parathyroid glands, muscle). With active D-analogs significant improvements in the therapeutic outcome of osteoporosis can be achieved by the resulting improvements of bone quality, calcium absorption and risk reduction of falling. The same beneficial effects cannot be achieved with plain vitamin D due to feedback controlled, limited renal activation or insufficient conversion in the elderly with impairment of renal function. Accordingly alfacalcidol, approved as a treatment for different forms of osteoporosis, is besides adoption as a mono-therapy an interesting candidate for combined therapies. There are interesting preclinical trials and clinical pilote studies in the literature proving that a parallel therapy with selectively anti-osteoclastic bisphophonates and pleiotropically acting D-analogs is able to optimize therapeutic results in osteoporosis. In the AAC-Trial (Alfacalcidol-Alendronate-Combined) we studied 90 patients with established osteoporosis (57 women, 33 men) over two years after alternate allocation to three treatment arms (alfacalcidol plus calcium, alendronate plus plain vitamin D and Ca, and alendronate plus alfacalcidol and Ca). During the 2-year-study we observed the significantly highest lumbar spine and hip BMD increases in the combined treatment group (p < 0.001). The number of patients with new vertebral and non-vertebral fractures after 2 years was 9 with alfacalcidol alone, 10 with alfacalcidol and plain vitamin D and 2 in the group receiving alendronate plus alfacalidol (p < 0.02). Furthermore there was a lower rate of falls and an earlier reduction in back pain in the patients treated with the active combination. This trial confirms the demonstrated highly significant advantages of this combined treatment regimen used in the pilote studies. Especially in patients with severe osteoporosis this interesting combination of two substances with complete different mechanisms of action should be taken into consideration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Youm T, Koval KJ, Kummer FJ, Zuckerman JD (1999) Do all hip fractures result from a fall? Am J Orthop 28:190–194

    PubMed  CAS  Google Scholar 

  2. Kaptoge S, Benevolenskaya LI, Bhalla AK, Cannata JB, Boonen S, Falch JA, Felsenberg D, Finn JD, Nuti R, Hoszowski K, Lorenc R, Miazgowski T, Jajic I, Lyritis G, Masaryk P (2005) Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. Bone 36:387–398. doi:10.1016/j.bone.2004.11.012

    Article  PubMed  CAS  Google Scholar 

  3. Runge M, Schacht E (2005) Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Musculoskelet Neuronal Interact 5:127–134

    PubMed  CAS  Google Scholar 

  4. Ringe JD (2006) Alfacalcidol in Prevention and Treatment of all Major Forms of Osteoporosis and Renal Osteopathy. Georg Thieme Verlag, Stuttgart

    Google Scholar 

  5. Ringe JD, Schacht E (2005) Natives vitamin D oder alfacalcidol? Prävention und Therapie von Osteoporosen. Arzneimitteltherapie 23:45–53

    CAS  Google Scholar 

  6. Schacht E (2008) Reduction of falls and osteoporotic fractures: Plain vitamin D or D-hormone analogs? Geriatr Gerontol Int 8(Suppl 1):S16–S25

    Google Scholar 

  7. Ringe JD (1999) Burckhardt P (eds) VitaminD/Calcium in der Osteoporosetherapie. Georg Thieme Verlag, Stuttgart

    Google Scholar 

  8. Mellanby E (1919) An experimental investigation of rickets. Lancet 1:407–411

    Google Scholar 

  9. Huldschinsky K (1919) Heilung von Rachitis durch künstliche Höhensonne. Dtsch med Wschr 45:712–717

    Google Scholar 

  10. DeLuca H (1978) Vitamin D metabolism and function. Arch Intern Med 138:836–847

    PubMed  CAS  Google Scholar 

  11. Wu-Wong JR, Tian J, Goltzman D (2004) Vitamin D analogs as therapeutic agents: a clinical study update. Curr Opin Investig Drugs 5:320–326

    PubMed  CAS  Google Scholar 

  12. Schacht E (1999) Rationale for treatment of involutional osteoporosis in women and prevention and treatment of corticosteroid-induced osteoporosis with Alfacalcidol. Calcif Tissue Int 65:317–327. doi:10.1007/s002239900705

    Article  PubMed  CAS  Google Scholar 

  13. DeLuca HF, Cantorna MT, Vitamin D (2001) Its Role and uses in immunology. FASEB J 15:2579–2585. doi:10.1096/fj.01-0433rev

    Article  PubMed  CAS  Google Scholar 

  14. Inanir A, Ozoran K, Tutkak H, Mermerci B (2004) The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis. J Int Med Res 32:570–582

    PubMed  CAS  Google Scholar 

  15. Scharla SH, Schacht E, Lempert UG (2005) Alfacalcidol versus plain vitamin D in inflammation induced bone loss. J Rheumatol 32:26–32

    Google Scholar 

  16. Kanis JA (1999) Vitamin D analogs: from renal bone disease to osteoporosis. Kidney Int 73(Suppl):S77–S81. doi:10.1046/j.1523-1755.1999.07317.x

    Article  CAS  Google Scholar 

  17. Ringe JD (ed) Calcium plus Vitamin D—Schlüsselrolle in der Osteoporose-behandlung. Georg Thieme Verlag, Stuttgart 2003

  18. Lips P (2004) Which level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 89–90:611–614. doi:10.1016/j.jsbmb.2004.03.040

    Article  PubMed  CAS  Google Scholar 

  19. Kipshoven C, Farahmand P, Ringe JD (2008) Zur Epidemiologie der vitamin D-Versorgung in Deutschland: Querschnittsuntersuchung an 1343 nicht selektierten Probanden (DeVID-Studie). Osteologie 1:A55

    Google Scholar 

  20. Misra B, McMahon DJ, Silverberg SJ, Bikezikian JP (2008) New data on the impact of renal function on the relation between 25-hydroxyvitamin D and parathyroid hormone. JBMR 23(Suppl):S10

    Google Scholar 

  21. Schacht E, Kneer W, Dambacher MA (2008) Die Wirkungen von Alfacalcidol auf den Muskel, das neuromuskulaere System, auf die Sturzgefahr und auf Frakturen. J Miner Stoffwechs 15(3):132–139

    Google Scholar 

  22. Bischoff HA, Borchers M, Gudat F (2001) In situ detection of 1, 25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 33:19–24

    Article  PubMed  CAS  Google Scholar 

  23. Boland R (1986) Role of vitamin D in skeletal muscle function. Endocrine Reviews 7:434–447

    Article  PubMed  CAS  Google Scholar 

  24. Bischoff-Ferrari HA, Borchers M, Gudat F, Dürmüller U, Stähelin HB, Dick W (2004) Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 19:265–269

    Article  PubMed  CAS  Google Scholar 

  25. Bischoff HA, Stähelin HB, Urscheler N (1999) Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 80:54–58

    Article  PubMed  CAS  Google Scholar 

  26. Dukas L, Schacht E, Bischoff HA (2003) Better functional mobility in community dwelling elderly is related to D-hormone and a minimal calcium intake of more than 512 mg/day. Osteoporos Int 14(7):S34

    Google Scholar 

  27. Sorenson OH, Lund B, Saltin B (1979) Myopathy in bone loss of aging: improvement by treatment with 1-alphahydroxycholecalciferol and calcium Clin Sci (Colch) 56:157–161

    Google Scholar 

  28. Verhaar HJJ, Samson MM, Jansen PAF, de Vreede PL, Manten JW, Duursma SA (2000) Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res 12:455–460

    CAS  Google Scholar 

  29. Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in prevention of age-related bone loss. J Clin Endocrinol Metab 86:3618–3628

    Article  PubMed  CAS  Google Scholar 

  30. Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN, Thalmann B, Stähelin HB (2004) Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. JAGS 52(2):230–236

    Article  Google Scholar 

  31. Dukas L, Schacht E, Mazor Z, Staehelin HB (2005) A new significant and independant risk factor for falls in elderly men and women: a low creatinine clearance of less than 65 ml/min. Osteoporosis Int 16:332–338

    Article  CAS  Google Scholar 

  32. Dukas L, Schacht E, Mazor Z, Stähelin HB (2005) Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos Int 16:198–203

    Article  PubMed  CAS  Google Scholar 

  33. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB (2004) Effect of vitamin D on falls. JAMA 291(16):1999–2006

    Article  PubMed  CAS  Google Scholar 

  34. Richy F, Dukas L, Schacht E (2008) Differential effects of D-hormone analogs and native vitamin D on the risk of falls: A comparative meta-analysis. Calcif Tissue Int 82:102–107

    Article  PubMed  CAS  Google Scholar 

  35. Hayashi Y, Fujita T, Inoue T (1992) Decrease of vertebral fracture in osteoporotics by administration of 1α-hydroxyvitamin D3. J Bon Miner Metab 10(2):50–54

    Article  Google Scholar 

  36. Tanizawa T, Imura K, Ishii Y, Nishida S, Takano Y, Mashiba T, Endo N, Takahashi HE (1999) Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study. Osteoporosis Int 9:163–170

    Article  CAS  Google Scholar 

  37. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, The osteoporosis methodology group, and the osteoporosis research advisory group (2002) Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570–578

    Article  PubMed  CAS  Google Scholar 

  38. Papadimitropoulos E, Wells G, Shea B (2002) Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocrine Reviews 23:560–569

    Article  PubMed  CAS  Google Scholar 

  39. Richy F, Ethgen O, Bruyere O, Reginster J-Y (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301–310

    Article  PubMed  CAS  Google Scholar 

  40. Mathieu C, Adorini L (2002) The coming age of 1, 25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends in Molecular Medicine 8:174–179

    Article  PubMed  CAS  Google Scholar 

  41. Henderson-Briffa K, Keogh A, Sambrook PN, Eismann JA (2003) Reduction by calcitriol of immunosuppressive therapy requirements in heart transplantation. Transplantation 75:2133–2134

    Article  CAS  Google Scholar 

  42. Van Staa TP, Leufkens HGM, Abenhaim A, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15(6):993–1000

    Article  PubMed  Google Scholar 

  43. Sasaki H, Miyakoshi N, Kasukama Y, Maekawa Y, Komo K, Shimada Y (2008) Effects of alfacalcidol on bone and skeletal muscle in glucocorticoid – treated rats. J Bone Mineral Res 23:s427

    Google Scholar 

  44. Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkes CJ, Nielsen K (1999) Prophylactic use of Alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 9:75–81

    Article  PubMed  CAS  Google Scholar 

  45. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, Speer G, Bossanyi A (2000) Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 59(Suppl 1:I):48–52

    Article  PubMed  Google Scholar 

  46. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, Tugwell P, Gordon M, Steele M, Webber C, Goldsmith CH (1996) Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year follow up. J Rheumatol 23:995–1000

    PubMed  CAS  Google Scholar 

  47. Shane E, Addesso V, Namerow P, McMahon D, Lo S, Staron R, Zucker M, Pardi S, Maybaum S, Mancini D (2004) Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767–776

    Article  PubMed  CAS  Google Scholar 

  48. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW (2004) Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 24:63–70

    Article  PubMed  CAS  Google Scholar 

  49. Ringe JD, Faber H, Farahmand P, Schacht E (2005) Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation –induced osteoporosis. J Rheumatol 32(Suppl 76):33–40

    Google Scholar 

  50. De Nijs RNJ, Jacobs JWG, Algra A, Lems WF, Bijlsma JWJ (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15:589–602

    Article  PubMed  CAS  Google Scholar 

  51. Ringe JD, Farahmand P, Schacht E (2008) Superiority of alfacalcidol over plain vitamin D in men with osteoporosis: a prospective, observational, single center, two year trial on 214 patients. J Bone Miner Res 23:S349

    Google Scholar 

  52. Gambacciani M, Spinetti A, Cappagli B, Ciaponi M, Gallo R, Rovati LC, Genazzani AR (1995) Effects of low-dose monofluorophosphate and transdermal oestradiol on postmenopausal vertebral bone loss. Europ Menopause J 2:16–20

    Google Scholar 

  53. Alexandersen P, Riis BJ, Christiansen C (1999) Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocriol Metab 84:3013–3020

    Article  CAS  Google Scholar 

  54. Ringe JD, Setnikar I (2002) Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study. Rheumatol Int 22:27–32

    Article  PubMed  CAS  Google Scholar 

  55. Lems WF, Jacobs JWG, Bijlsma WJ, van Veen GJM, Houben HHML, Haanen HCM, Gerrits MI, van Rijn HJM (1997) Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticoid induced osteoporosis? Ann Rheumatol Dis 56:357–363

    Article  CAS  Google Scholar 

  56. Ringe JD, Rovati L (2001) Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 69:252–255

    Article  PubMed  CAS  Google Scholar 

  57. Morabito N, Gaudio A, Lasco A, Vergara C, Tallarida F, Crisafulli G, Trifiletti A, Cincotta M, Pizzoleo MA, Frisina N (2003) Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporos Int 14:500–506

    Article  PubMed  CAS  Google Scholar 

  58. Ringe JD, Dorst A, Faber H, Kipshoven C, Rovati LC, Setnikar I (2005) Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study. Rheumatol Int 25:296–300

    Article  PubMed  CAS  Google Scholar 

  59. Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T (2003) Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int 14:741–749

    Article  PubMed  CAS  Google Scholar 

  60. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH (1995) The anabolic effect of human PTH (1–34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronat. Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603–610

    Article  PubMed  CAS  Google Scholar 

  61. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxseri ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215

    Article  PubMed  CAS  Google Scholar 

  62. Frediani B, Allegri A, Bisogno S, Marcolongo R (1998) Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis two years of continuous treatment. Clin Drug Invest 15:235–244

    Article  CAS  Google Scholar 

  63. Azuma Y, Takagi H, Ohta T, Kawaguchi H (2002) Curative effect of combined treatment with alendronate and 1α-hydroxyvitamin D on bone loss by ovariectomy in aged rats. Jpn J Pharmacol 89:255–266

    Article  PubMed  Google Scholar 

  64. Ringe JD, Farahmand P, Schacht E, Rozenal A (2007) Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27:425–434

    Article  PubMed  CAS  Google Scholar 

  65. Ringe JD, Schacht E (2007) Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol. Rheumatol Int 28:103–111

    Article  PubMed  CAS  Google Scholar 

  66. Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N (1994) Effects of 1-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370–376

    Article  PubMed  CAS  Google Scholar 

  67. Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of post-menopausal osteoporosis with calcitriol or calcium. New Engl J Med 326(6):357–362

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. West-German Osteoporosis Center (WOC) and Med. Clinic 4, Klinikum Leverkusen, University of Cologne, 51375, Leverkusen, Germany

    J. D. Ringe & E. Schacht

Authors
  1. J. D. Ringe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Schacht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. D. Ringe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ringe, J.D., Schacht, E. Potential of alfacalcidol for reducing increased risk of falls and fractures. Rheumatol Int 29, 1177–1185 (2009). https://doi.org/10.1007/s00296-008-0835-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-008-0835-x

Keyword

Search

Navigation